Tempest Therapeutics, Inc. (TPST) stock
TPSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.38−0.01 (-3.53%)
Close on Nov 12, 2026Market cap $5.67MP/E –Yield –
Tempest Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Tempest Therapeutics's gross margin for the twelve months ending Sep 30, 2018 was -45.6%. For fiscal 2017 it was -167.8%, against -727.1% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | -167.8% | +559.3 |
| FY2016 | Dec 31, 2016 | -727.1% | −15.2 |
| FY2015 | Dec 31, 2015 | -711.9% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2018 | Sep 30, 2018 | 20.0% | −28.2 |
| Q2 FY2018 | Jun 30, 2018 | 33.3% | +259.5 |
| Q1 FY2018 | Mar 31, 2018 | -67.2% | +259.8 |
| Q4 FY2017 | Dec 31, 2017 | -139.6% | +944.7 |
| Q3 FY2017 | Sep 30, 2017 | 48.2% | +739.6 |
| Q2 FY2017 | Jun 30, 2017 | -226.2% | – |
| Q1 FY2017 | Mar 31, 2017 | -327.0% | – |
| Q4 FY2016 | Dec 31, 2016 | -1084.3% | – |
| Q3 FY2016 | Sep 30, 2016 | -691.4% | – |
See a number that looks wrong?